Hepatic arterial iodine-131-labeled metuximab injection combined with chemoembolization for unresectable hepatocellular carcinoma: interim safety and survival data from 110 patients.

Abstract

Few options are available to treat patients with hepatocellular carcinoma (HCC). It was tested whether the combination of iodine-131(¹³¹I)-metuximab with chemoembolization could improve outcomes in patients with intermediate HCC. Between April 2008 and April 2009, 110 patients with unresectable HCC were treated with 113 intra-arterial ¹³¹I-metuximab injections combined with chemoembolization (mean, 1.03 per patient; median, 1; range, 1-2), followed by 264 sessions of transcatheter arterial chemoembolization (mean, 2.4 per patient; median, 3; range, 1-6). The survival rates at 6, 12, and 18 months were 88.2%, 79.1%, and 57.4%, respectively, by the Kaplan-Meier method. Of these patients, 12% exhibited grade 3/4 bilirubin toxicity, 5% exhibited grade 3/4 white blood count toxicity, and 7% exhibited grade 3/4 platelet toxicity. Response rates based on World Health Organization and European Association for the Study of the Liver criteria were 42.73% and 61.82%, respectively. The combination of ¹³¹I-metuximab and chemoembolization appeared to extend survival in patients with unresectable HCC compared with historical controls, as well as being well tolerated by patients with Child-Pugh A and B. This combination may represent a promising treatment modality for patients with intermediate HCC.

• Authors: Lu Wu, Ye-Fa Yang, Nai-Jian Ge, Shu-Qun Shen, Jun Liang, Yi Wang, Wei-Ping Zhou, Feng Shen, Meng-Chao Wu
• Journal: Cancer biotherapy & radiopharmaceuticals (Cancer Biother Radiopharm) Vol. 25 Issue 6 Pg. 657-63 (Dec 2010) ISSN: 1557-8852 [Electronic] United States
• PMID: 21204759 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal
• Immunotoxins
• metuximab

Topics

• Adult
• Aged
• Aged, 80 and over
• Antibodies, Monoclonal (administration & dosage, adverse effects, therapeutic use)
• Carcinoma, Hepatocellular (diagnostic imaging, mortality, pathology, therapy)
• Chemoembolization, Therapeutic (adverse effects, methods)
• Female
• Hepatic Artery
• Humans
• Immunotoxins (administration & dosage, adverse effects, therapeutic use)
• Injections, Intra-Arterial
• Kaplan-Meier Estimate
• Liver Neoplasms (diagnostic imaging, mortality, pathology, therapy)
• Male
• Middle Aged
• Neoplasm Staging
• Radionuclide Imaging
• Survival Rate
• Treatment Outcome